We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

259 hedge funds and large institutions have $2.75B invested in Pacira BioSciences in 2021 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 95 increasing their positions, 90 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

192% more call options, than puts

Call options by funds: $6.09M | Put options by funds: $2.09M

6% more repeat investments, than reductions

Existing positions increased: 95 | Existing positions reduced: 90

0% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 25

1% less funds holding

Funds holding: 262 → 259 (-3)

1.62% less ownership

Funds ownership: 112.14% → 110.52% (-1.6%)

8% less capital invested

Capital invested by funds: $2.99B → $2.75B (-$242M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
259
Holders Change
-3
Holders Change %
-1.15%
% of All Funds
4.53%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
25
Increased
95
Reduced
90
Closed
25
Calls
$6.09M
Puts
$2.09M
Net Calls
+$4.01M
Net Calls Change
+$960K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$53.9M
2
CS
Candriam SCA
Luxembourg
+$11.8M
3
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$5.51M
4
SCM
Spyglass Capital Management
California
+$5.39M
5
Invesco
Invesco
Georgia
+$4.92M

Top Sellers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
-$22.2M
2
Two Sigma Investments
Two Sigma Investments
New York
-$14.8M
3
SPPAM
Summit Partners Public Asset Management
Massachusetts
-$13.7M
4
DM
Deerfield Management
New York
-$10.4M
5
Morgan Stanley
Morgan Stanley
New York
-$9.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
CCA
226
Column Capital Advisors
Indiana
$12K – – –
NL
227
NVWM LLC
Pennsylvania
$11K – – –
Daiwa Securities Group
228
Daiwa Securities Group
Japan
$9K +$4.03K +70 +85%
CFA
229
Carroll Financial Associates
North Carolina
$8K – – –
GWM
230
Geneos Wealth Management
Colorado
$8K – – –
QCG
231
Quadrant Capital Group
Ohio
$8K +$346 +6 +4%
LWM
232
Liberty Wealth Management
California
$8K +$4.38K +76 +115%
PFBT
233
Parkside Financial Bank & Trust
Missouri
$7K +$231 +4 +3%
SWM
234
Spire Wealth Management
Virginia
$6K -$28.8K -500 -83%
ARMC
235
American Research & Management Company
Massachusetts
$6K – – –
APWA
236
Atlas Private Wealth Advisors
New Jersey
$6K – – –
TWA
237
TCI Wealth Advisors
Arizona
$6K +$1.27K +22 +26%
Walleye Capital
238
Walleye Capital
New York
$5.08K -$210K -3,636 -4%
PHK
239
Point72 Hong Kong
Hong Kong
$5K -$376K -6,530 -99%
FF
240
FourThought Financial
Florida
$4K – – –
FRA
241
Front Row Advisors
California
$4K – – –
Fidelity Investments
242
Fidelity Investments
Massachusetts
$4K +$231 +4 +6%
CFA
243
Cahill Financial Advisors
Minnesota
$4K +$3.8K +66 New
DFCM
244
Dark Forest Capital Management
Puerto Rico
$4K +$4.61K +80 New
FPS
245
Fieldpoint Private Securities
Connecticut
$3K -$2.02K -35 -39%
RMC
246
Resources Management Corp
Connecticut
$3K – – –
S
247
SignatureFD
Georgia
$2K – – –
PCG
248
Private Capital Group
Connecticut
$2K +$749 +13 +68%
ACM
249
Anfield Capital Management
California
$1K +$634 +11 New
CI
250
Cordant Inc
Oregon
$1K +$922 +16 New
8 9
10
11 12

PCRX Hedge Fund Activity: Q3 2021 in Review

259 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2021, worth a combined $2.75B — down 8.1% from $2.99B a quarter earlier.

Fund positioning in PCRX was balanced in Q3 2021: 25 funds opened new positions, 25 closed out, 95 added to existing stakes and 90 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $53.9M. The largest seller was Wells Fargo, cutting an estimated $22.2M.

  • 259 institutional investors held Pacira BioSciences (PCRX) as of Q3 2021, down from 262 in Q2 2021.
  • Funds reported $2.75B of Pacira BioSciences stock for Q3 2021, down 8.1% quarter-over-quarter.
  • 25 funds opened new Pacira BioSciences positions in Q3 2021 and 25 closed out, a net change of 0 holders.
  • The largest Pacira BioSciences buyer in Q3 2021 was Armistice Capital, an estimated $53.9M added.
  • The largest Pacira BioSciences seller in Q3 2021 was Wells Fargo, an estimated $22.2M sold.

Based on aggregated 13F filings for Q3 2021.